Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy

Fluoropyrimidines (FPs), mainly 5-fluorouracil (5-FU) and its oral prodrug capecitabine (Cap), remain the backbone of the treatment of many different solid tumors. Despite their broad use in clinical routine, 10–40% of patients experience severe, and in rare cases (0.2–0.5%) even lethal, FP-relate...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Seid Hamzic, Stefan Aebi, Markus Joerger, Michael Montemurro, Marc Ansari, Ursula Amstutz, Carlo Largiadèr
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2020-11-01
Sarja:	Swiss Medical Weekly
Aiheet:	fluoropyrimidines 5-fluorouracil capecitabine therapeutic drug monitoring chemotherapy pharmacogenomics
Linkit:	https://www.smw.ch/index.php/smw/article/view/2899
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!